Stock price of NeoGenomics, Inc. (OTC:NGNM) has been frozen over the past days. After a 4.55% gain on Tuesday, it stopped at 
$1.15 per share and has not changed since then. Though, traded volume of NGNM is constantly increasing and the next move of the stock is eagerly expected.
NeoGenomics claims to be a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing. The company has not released any news on its business lately, apart from its quarterly results that were announced yesterday.
According to the company’s press release, NGNM has achieved a 30% growth in revenue, 40% of which fell to the bottom line, and the net loss was reduced.[BANNER]
However, the selling, general and administrative expenses have increased by 2.7%, while the net loss remained uncovered.
Meanwhile, during the last few months the Chairman and CEO of NeoGenomics has been regularly acquiring different amount of the company’s shares of common stock, which most probably influenced NGNM stock price.
Presently, NeoGenomics is expecting high revenue, while its previous 10-Q is full of risk factors concerning the company’s business, which are beyond its control.
